1Arkema A, Huckriede A, Schoen P, et al. Induction of cytotxic T lymphocyte activity by fusion-active peptlde-containing virosomes [J]. Vaccine, 2000, 18 (14) : 1327-1333.
3Gluck R, Metcalfe IC. New technology platforms in the development of vaccines for future[J]. Vaccine, 2002, 20 ( suppl 5 ) : B10- 16.
4Gnp-ta RK, Relyveld EH, Lindblad EB, et al. Ajuvants-a balance between toxicity and adjuvanticity [ J]. Vaccine, 1993, 11 (3) : 293-306.
5Gluck R, Mesch|er R, Brantsehen S, et al. Immunopotentiating reconstituted influenza vires virosome vaccine delivery system for immunization against hepatitis A [J]. J Clin Invest, 1992, 90 (6) : 2491-2495.
6Loutan L, Bovier P, Althaus B, et al. Inactivated virosome hepatitis A vaccine [J]. Lancet, 1994, 343 (8893) : 322-324.
7Bovier PA, Althaus B, Glueck R, et al. Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccine [J].J Travel Med, 1999, 6 (4): 228- 233.
8Usonis V, Bakasenas, V, Valentelis R, et al. Antibody titres after primary and booster vaccination of infants and young childem with a vlrosomal hepatitis A vaccine ( Epaxal ) [J] . Vaccine, 2003, 21 (31) : 4588-4592.
9Ridemann S, Reinhardt G, Iharm H, et al. Immunogenieity and safety of a virosomal hepatitis A vaccine (Epaxal) in healthy teddiets and children in Chile [J]. Aeta Pediatr, 2004, 93 (3) : 412-414.
10Mayorga Perez O, Herzog C, Zellmeyer M, et al. Efficacy of virosome hepatitis A vaccine in young children in incaragua: randomized placebo.controlled trial [J].J Infect Dis, 2003, 188 (5): 671-677.
